Your browser doesn't support javascript.
loading
Invasive Candida infection: epidemiology, clinical and therapeutic aspects of an evolving disease and the role of rezafungin.
Oliva, Alessandra; De Rosa, Francesco Giuseppe; Mikulska, Malgorzata; Pea, Federico; Sanguinetti, Maurizio; Tascini, Carlo; Venditti, Mario.
Afiliación
  • Oliva A; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
  • De Rosa FG; Department of Medical Sciences, University of Turin, Infectious Diseases, City of Health and Sciences, Turin, Italy.
  • Mikulska M; Division of Infectious Diseases Department of Health Sciences (DISSAL), University of Genoa IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Pea F; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
  • Sanguinetti M; Clinical Pharmacology Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.
  • Tascini C; Department of Laboratory Sciences and Infectious Diseases, Fondazione Policlinico Universitario "A. Gemelli"; IRCCS, Università Cattolica Del Sacro Cuore, Rome, Italy.
  • Venditti M; Infectious Diseases Clinic: Department of Medical Area (DAME), University of Udine, Udine, Italy.
Expert Rev Anti Infect Ther ; 21(9): 957-975, 2023.
Article en En | MEDLINE | ID: mdl-37494128
INTRODUCTION: Invasive Candida Infections (ICIs) have undergone a series of significant epidemiological, pathophysiological, and clinical changes during the last decades, with a shift toward non-albicans species, an increase in the rate of exogenous infections and clinical manifestations ranging from candidemia to an array of highly invasive and life-threatening clinical syndromes. The long-acting echinocandin rezafungin exhibits potent in-vitro activity against most wild-type and azole-resistant Candida spp. including C.auris. AREAS COVERED: The following topics regarding candidemia only and ICIs were reviewed and addressed: i) pathogenesis; ii) epidemiology and temporal evolution of Candida species; iii) clinical approach; iv) potential role of the novel long-acting rezafungin in the treatment of ICIs. EXPERT OPINION: Authors' expert opinion focused on considering the potential role of rezafungin in the evolving context of ICIs. Rezafungin, which combines a potent in-vitro activity against Candida species, including azole-resistant strains and C.auris, with a low likelihood of drug-drug interactions and a good safety profile, may revolutionize the treatment of candidemia/ICI. Indeed, it may shorten the length of hospital stays when clinical conditions allow and extend outpatient access to treatment of invasive candidiasis, especially when prolonged treatment duration is expected.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Candidemia / Candidiasis Invasiva Tipo de estudio: Screening_studies Límite: Humans Idioma: En Revista: Expert Rev Anti Infect Ther Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2023 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Candidemia / Candidiasis Invasiva Tipo de estudio: Screening_studies Límite: Humans Idioma: En Revista: Expert Rev Anti Infect Ther Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2023 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido